Gastrin and its precursors promote proliferation in different gastrointestinal cells. Since mature, amidated gastrin (G-17) can induce cyclin D1, we determined whether G-17-mediated induction of cyclin D1 transcription involved Wnt signaling and CRE-binding protein (CREB) pathways. Our studies indicate that G-17 induces protein, mRNA expression and transcription of the G 1 -specific marker cyclin D1, in the gastric adenocarcinoma cell line AGSE (expressing the gastrin/cholecystokinin B receptor). This was associated with an increase in steadystate levels of total and nonphospho b-catenin and its nuclear translocation, indicating the activation of the Wnt-signaling pathway. In addition, G-17-mediated increase in cyclin D1 transcription was significantly attenuated by axin or dominant-negative (dn) T-cell factor 4(TCF4), suggesting crosstalk of G-17 with the Wnt-signaling pathway. Mutational analysis indicated that this effect was mediated through the cyclic AMP response element (CRE) (predominantly) and the TCF sites in the cyclin D1 promoter, which was also inhibited by dnCREB. Furthermore, G-17 stimulation resulted in increased CRE-responsive reporter activity and CREB phosphorylation, indicating an activation of CREB. Chromatin immunoprecipitation studies revealed a G-17-mediated increase in the interaction of b-catenin with cyclin D1 CRE, which was attenuated by dnTCF4 and dnCREB. These results indicate that G-17 induces cyclin D1 transcription, via the activation of b-catenin and CREB pathways.
Introduction
Gastrointestinal (GI) tract tumors contribute significantly to overall cancer mortality throughout the world. Colorectal cancers rank third of all cancer-related deaths in the United States (Greenlee et al., 2000) and gastric cancers rank second worldwide (Pisani et al., 1999) . Studies during the past two decades have demonstrated that the GI peptide hormone gastrin might play key roles in regulating both normal as well as malignant GI growth (Rozengurt and Walsh, 2001 ). This is of clinical importance since an increase in serum gastrin levels is a common side effect following Helicobacter pylori (H. pylori) infection (Smith et al., 1990; Konturek et al., 2000) , or the use of proton pump inhibitors (PPIs) (Lind et al., 1988) . Both antral-and tumor-derived gastrin, as well as unprocessed forms (progastrin and glycine-extended gastrin) are capable of stimulating cell proliferation (Seva et al., 1994; Singh et al., 2000) . However, controversies do exist with regard to the precise involvement of gastrin in the tumorigenic pathway. In two recent studies with gastric cancer cells, gastrin stimulated growth in one (Song et al., 2003) and inhibited growth in the other (Varro et al., 2002) . Hypergastrinemia-related studies with Omeprazole also provided conflicting results. While Omeprazole-induced hypergastrinemia was unable to increase tumor incidence in a colon cancer model in rats (Penman et al., 1993; Pinson et al., 1995) , it promoted the growth of colorectal adenocarcinoma in APC Min/ þ mice, associated with a significant decrease in survival, which was reversed by the antigastrin antibody, Gastrimmune (Watson and Smith, 2001) . A recent epidemiological study showed that prolonged hypergastrinemia increased the relative risk of developing colon cancer by 3.3-fold (Thorburn et al., 1998) . Transgenic mice overexpressing the amidated forms of gastrin showed increased proliferation and hypertrophy of gastric mucosa (Wang et al., 1996) , which synergized with H. pylori infection and enhanced the development and progression of invasive gastric cancer . In addition, G17DT or Gastrimmune, which has been shown to exert strong therapeutic effects towards primary as well as metastatic colorectal cancers, is currently under phase III clinical trials for treatment of GI-related cancers (Watson and Gilliam, 2001) . A link between hypergastrinemia and gastric cancer (particularly those with neuroendocrine differentiation) has been suggested in other studies as well (Miyaji et al., 1997; Qvigstad et al., 2002) . These conflicting reports indicate the need for further studies to establish a direct link between the gastrin pathway and tumorigenesis.
Malignant transformation occurs in multiple steps, where normal epithelial cells undergo dysplastic transformation, followed by uncontrolled proliferation and progression to neoplasia. A set of proteins known as cyclins (particularly cyclin D) contributes towards this process, by controlling G 1 /S transition, via regulating the activity of the cyclin-dependent kinases (CDK4 and CDK6) . Recent studies have shown increased expression of cyclin D1 in the presence of amidated gastrin (G-17) (Zhukova et al., 2001; Song et al., 2003) , although the detailed mechanism(s) involved is unknown. In addition, H. pylori infection, which can lead to gastric cancer and is associated with hypergastrinemia also induces cyclin D1 transcription (Hirata et al., 2001) . Elucidation of the pathway of G-17-mediated induction of cyclin D1 expression is extremely important in view of the increasing number of reports demonstrating a close link of cyclin D1 overexpression with GI-related malignancies (Oda et al., 1999) and will contribute towards our understanding of G-17-mediated pathways.
Since the involvement of gastrin in regulating the cellcycle events is largely unexplored, we have undertaken studies in a gastric adenocarcinoma cell line (AGSE) overexpressing the cholecystokinin B (CCKB) receptor, with the aim to study its effect on the cell-cycle regulatory protein cyclin D1 and to identify the effectors involved. Our results indicate that addition of G-17 to AGSE cells resulted in significant induction of cyclin D1 transcription associated with a corresponding increase in the steady-state levels and nuclear translocation of bcatenin and activation of CRE-binding protein (CREB). G-17-induced cyclin D1 transcription was attenuated following overexpression of axin or dominant-negative (dn) T-cell factor 4(TCF4) and dnCREB (KCREB) and was mediated through the CRE site (predominantly) as well as the TCF sites in the cyclin D1 promoter. Chromatin immunoprecipitation (ChIP) studies detected an interaction of b-catenin with cyclin D1 CRE, which was increased by G-17 and inhibited by dnTCF4 and dnCREB. Our results demonstrated that G-17-mediated activation of the cyclin D1 promoter involves crosstalk with the Wnt-signaling and CREB pathways.
Results

G-17 increases G 1 /S progression in AGSE cells
To elucidate the mechanism by which G-17 induced cell growth in the gastric cancer cells (Song et al., 2003) , we determined the effect of G-17 on cell-cycle progression in AGSE cells. Serum-starved AGSE cells, treated in the presence or absence of G-17, were stained with propidium iodide and the DNA content was determined by flow cytometry. In the absence of G-17, the AGSE cells were arrested in G 1 (Figure 1 , 77.24% at 6 h and 78.48% at 24 h, G-17À cells). The addition of G-17 to these cells resulted in a decrease in G 1 population (24 h 78.48% in G-17À vs 66.23% in G-17 þ ) and a corresponding increase in S phase population (24 h 13.52% in G-17À vs 25.77% in G-17 þ ). These results indicated an activation of G 1 /S progression in AGSE cells following incubation with G-17.
G-17 induces cyclin D1 transcription and activates the Wnt-signaling pathway in AGSE cells
Since the addition of G-17 to the AGSE cells resulted in G 1 /S progression, we examined the effect of G-17 on the G 1 phase regulatory protein cyclin D1 in these cells. The estimation of cyclin D1 levels by Western blots ( Figure  2a and b), Immunofluorescence analysis ( Figure 2c ) and Northern blots (data not shown) indicated increased expression of cyclin D1 protein as well as mRNA, following the addition of G-17 to the AGSE cells. Luciferase assays carried out using the full-length human cyclin D1 promoter linked to a luciferase reporter (À1745 CD1-luc; Watanabe et al., 1996) showed a dramatic increase in À1745 CD1-luc promoter activity with increasing concentrations of G-17, being maximal at 100 nM, (Figure 2d , lanes 3-7), which was completely attenuated by the CCKB receptor-specific antagonist L365,260 (lanes 7 and 8), with minor effect on the activity of the empty pA3-luc promoter, used as control (lanes 1 and 2). These studies indicated that Since cyclin D1 is a direct target of the b-catenin/ lymphoid enhancer factor (LEF)-mediated pathway (Tetsu and McCormick, 1999) , we determined whether G-17 could induce cyclin D1 transcription, via the activation of the Wnt-signaling pathway. To address this, we first determined the effect of G-17 on b-catenin expression, by Western blot analysis of AGSE wholecell protein extracts, treated without (À) or with ( þ ) 100 nM G-17, using antibodies specific to total b-catenin, as well as N-terminally dephosphorylated/activated bcatenin (ABC b-catenin), as reported previously (Staal et al., 2002) . The results indicated significant induction of dephosphorylated/activated b-catenin (Figure 3c , À and þ lanes) and minor induction of total b-catenin (Figures 3a and b) following G-17 stimulation, which was associated with an increase in b-catenin nuclear translocation (Figure 3d , compare V panel with G-17 panel). These results suggested an activation of the Wntsignaling pathway following the addition of G-17.
G-17-mediated induction of cyclin D1 transcription involves the Wnt-signaling pathway
To determine any involvement of Wnt pathway in G-17-activated cyclin D1 transcription, we inhibited Wnt signaling in AGSE cells by overexpressing either axin or dnTCF4, since they have been used by various investigators to block the Wnt-signaling pathway (Kolligs et al., 1999; Ross et al., 2000) . Axin is known to inhibit Wnt-signaling pathway via facilitating the phosphorylation and thus the degradation of b-catenin (Kikuchi, 1999) and dnTCF4 functions as a dn for Wnt pathway (Korinek et al., 1997) . Cyclin D1 luciferase assays performed in the presence of axin, dnTCF4 or the empty vector (EV) demonstrated a significant attenuation of G-17-activated cyclin D1 transcription in the presence of either axin or dnTCF4 (Figure 4a , compare lanes 3 and 4, 5 and 6 with lanes 1 and 2). Similar studies performed with increasing concentrations of the plasmid vector overexpressing axin indicated that 1 mg of the axin expression plasmid was optimal to block more than 50% of the effect of G-17 on cyclin D1 transcription (Figure 4b ), suggesting that G-17-induced cyclin D1 transcription involves the Wnt-signaling pathway. However, cyclin D1 luciferase assays carried out in the presence of different EV controls showed no effect on G-17-mediated induction of promoter activity (Figure 4c ), indicating the specificity of axin and dnTCF4 effects.
G-17-mediated induction of cyclin D1 transcription involves the CRE site
We then designed studies to determine whether G-17 activated cyclin D1 transcription via the TCF or the CRE site in the promoter. Luciferase assays performed with the À66 cyclin D1-luc construct (lacking the TCF/ LEF site at 81 bp, while retaining the CRE/ATF2 site at 58 bp) (Watanabe et al., 1996) indicated a G-17-mediated activation of À66 CD1-luc activity ( Figure 5a , compare lanes 1 and 2 with lanes 3 and 4), even in the absence of TCF sites. Additional luciferase assays performed with À1745 CD1-luc constructs, containing point mutations at either the TCF (À1745 CD1-TCFmut) or the CRE site (À1745 CD1-CREmut), showed that while mutation of the CRE site almost completely blocked G-17-mediated induction of cyclin D1 promoter activity ( Figure 5a , compare lanes 1 and 2 with lanes 7 and 8), mutation of the TCF site did not (lanes 5 and 6). These results confirmed that G-17 stimulation activated the cyclin D1 promoter, via a major interaction with the CRE site. To determine the effect of G-17 on TCF-and CRE-mediated pathways, separate luciferase assays were designed with either TCF-responsive luciferase reporters pGL3OT (containing wild type TCF sites) or pGL3OF (containing mutant TCF sites) and CRE-responsive reporter pCRE-luc. These results indicated a major activation of the CRE pathway (Figure 5b , lanes 7 and 8) and minor activation of the TCF pathway, by G-17 (lanes 3 and 4, 5 and 6). In addition, G-17-induced CRE-responsive reporter activity was significantly inhibited in the presence of dnTCF4 (Figure 5c ), without any effect on the TCF-responsive reporters. EMSA studies performed with TCF sitespecific oligonucleotide showed no change in TCF binding by G-17 (data not shown), suggesting that G-17-mediated pathway involved predominantly the CRE site.
G-17 induces cyclin D1 transcription via CREB
The transcription factors capable of binding to the CRE sites of target gene promoters include CREB, ATF2 and others, depending on the type and growth state of the cells . Since CREB plays a major role in regulating cyclin D1 transcription through certain , we designed studies to determine whether CREB was involved in mediating the G-17 effects on cyclin D1 promoter activation. These studies showed a significant attenuation of G-17-induced cyclin D1 transcription in the presence of dnCREB (KCREB) (Figure 6a , compare lanes 1 and 2 with lanes 5 and 6 and lanes 3 and 4 with lanes 7 and 8), indicating the participation of CREB in these events.
The activation of CREB involves its phosphorylation at serine 133 , resulting in the recruitment of CBP and activation of the CRE (Mayr and Montminy, 2001 ). Western analysis of AGSE extracts demonstrated a potent increase in serine 133 phosphorylation, indicating an activation of CREB by G-17, at all time points tested (Figure 6b, À and þ lanes, phospho-CREB panel), without any change in total CREB levels (total CREB panel). Luciferase studies also showed that although dnTCF4 and KCREB attenuated G-17-mediated cyclin Figure 7a and lanes 5 and 6 in Figure 7b ), which was attenuated in the presence of either dnCREB or dnTCF4 (compare lanes 8 and 9 with lane 7 in Figure 7a and lanes 7 and 8 with lane 6 in Figure 7b ). The ChIP results in Figure 7c showed the absence of the same PCR fragment in a mock IP or no antibody IP control, and its presence in the corresponding input sample.
Since both b-catenin and CREB (Mayr and Montminy, 2001 ) can bind to the CRE site (Figure 7a and b), we hypothesized that they might interact with each other. To determine any interaction between bcatenin and CREB and whether G-17 can effect this interaction, we immunoprecipitated total CREB from AGSE cells treated in the presence ( þ ) or absence (À) of G-17 for the indicated periods of time, followed by SDS-PAGE and Western blot analysis with total bcatenin antibody. These results indicated an in vivo interaction between CREB and b-catenin, which was increased following the addition of G-17 (Figure 8a 
Discussion
The GI peptide hormone gastrin has been shown to regulate multiple cellular functions, including growth, apoptosis and secretion (Rozengurt and Walsh, 2001) . Although the participation of G-17 in cellular proliferation is debatable, two recent studies have shown increased proliferation by G-17 in gastric cells (Hollande et al., 2001; Song et al., 2003) . The fact that G-17 can induce cyclin D1 expression (Zhukova et al., 2001; Song et al., 2003) indirectly reveals its growth-promoting/ oncogenic function, since cyclin D1 functions as an oncogene in several kinds of tumor tissues (Motokura and Arnold, 1993), and new evidence suggests a role in invasion as well (Arato-Ohshima and Sawa, 1999; Jung et al., 2001) . The CCK2 receptor (Watson et al., 2000) and gastrin (Bierkamp et al., 2002; Noble et al., 2003) have been implicated in regulating the invasion pathway as well. The elucidation of the pathway by which G-17 4) , KCREB (lanes 7 and 8) or both (lanes 11 and 12) and treated as in (a). Similar amounts of pcDNA3.1 or pRC/RSV cDNAs were used as EV controls, for dnTCF4 and KCREB, respectively. The data (both a and c) represent the mean7s.d. of three independent experiments performed in triplicate, *Po0.0001 compared to untreated controls induced cyclin D1 levels should thus provide a significant insight into the mediators involved in G-17-activated events. In fact, our studies revealing a G-17-mediated activation of Wnt pathway is of clinical importance considering b-catenin (Wnt pathway member) is an important oncogene for GI-related tumorigenesis (Bienz and Clevers, 2000) .
The mechanism by which G-17 induces cyclin D1 transcription has not been defined previously. Our studies using EMSA with a TCF -site-specific oligo (data not shown) and À1745 CD1 luciferase assays with CD1-luc mutant constructs (À66 CD1, À1745 CD1-TCFmut or À1745 CD1-CREmut) indicated that G-17-mediated activation of the cyclin D1 promoter involved predominantly the CRE site. However, a partial contribution of the TCF site cannot be completely excluded. The observation that the CRE element played a key role in gastrin-mediated induction of downstream promoters (Thommesen et al., 2001) further strengthened our observation. Our observation that G-17/bcatenin-mediated induction of cyclin D1 transcription primarily involved the CRE pathway was not unusual, since the Wnt-responsive gene, WISP-1, was also shown to be activated by a TCF-independent and CREdependent pathway (Xu et al., 2000) . Our studies showing an inhibition of G-17-activated cyclin D1 transcription following the cotransfection of dnCREB established the participation of CREB in G-17 pathway. G-17 stimulation also activated CREB as evident from increased CREB serine 133 phosphorylation. The fact that cotransfection of dnTCF4 and dnCREB together did not show any synergistic effect in attenuating G-17-mediated cyclin D1 transcription suggested that both converged on the same site at the cyclin D1 promoter (possibly the CRE site). Results from the ChIP studies indicated that b-catenin was capable of interacting with the cyclin D1 CRE, which was increased by G-17 and attenuated by dnCREB and dnTCF4. Since CREB is known to bind to the CRE site directly, it was conceivable that b-catenin associated with cyclin D1 CRE, via interaction with CREB. Inhibition of G-17 induced b-catenin binding to cyclin D1 CRE by dnCREB and data showing an interaction between CREB and b-catenin supported this hypothesis.
The mechanism by which G-17 increased interaction between CREB and b-catenin resulting in increased cyclin D1 transcription is still unclear. This might involve CBP, since CBP can bind to and act as a coactivator for both b-catenin (Hecht et al., 2000; Takemaru and Moon, 2000) and CREB (Parker et al., 1996) . It is conceivable that following G-17 stimulation CBP recruits both activated b-catenin and CREB to the CRE site, resulting in increased CRE-mediated transcription. However, since the binding sites for b-catenin (a.a. 451-682) and CREB (a.a 586-679) on CBP are overlapping, it is possible that CBP might indirectly affect CREB/b-catenin interaction as discussed below. It has been shown that Drosophila dCBP can interact with dTCF (Waltzer and Bienz, 1998) , which via acetylation of dTCF reduces the affinity of dTCF for Armadillo and thus negatively regulates wingless signaling. Interestingly, in our studies the addition of dnTCF4 inhibited G-17-induced pCRE-luc reporter activity and b-catenin association with cyclin D1 CRE (Figures 5c and 7a and  b) . dnTCF4 expresses a truncated TCF4 protein with an N-terminal deletion at the b-catenin-binding site (Korinek et al., 1997) , but retains DNA-binding capability and thus the binding site for CBP (Waltzer and Bienz, 1998) . It is thus possible that upon stimulation by G-17, CBP inhibited TCF binding to bcatenin, resulting in increased binding of b-catenin to CREB. Ectopic overexpression of dnTCF4 might result in competition between dnTCF4 and TCF4 for CBP binding, thus releasing TCF4 from the inhibitory effect of CBP. Free TCF4 can then compete with CREB for bcatenin binding, resulting in reduced CREB/b-catenin binding (Figure 8b ) and thus reduced pCRE-luc activity (Figure 5c ). Further experiments are necessary to establish the involvement of CBP in G-17-mediated effects and to determine how dnTCF4 abrogated b-catenin and CREB interaction.
It remains unclear how G-17 regulated the activity and levels of b-catenin. Our studies showed a potent activation of AKT (downstream component of phosphatidylinositol 3-kinase (PI3Kinase)) and a corresponding inactivation of GSK3b by G-17 in these cells (data not shown). Since the aABC b-catenin antibody is directed towards N-terminal nonphosphorylated bcatenin and since G-17 induced levels of dephosphorylated b-catenin, it is possible that G-17-mediated inhibition of GSK3b resulted in increased N-terminal dephosphorylation of b-catenin and allowed its translocation to the nucleus (Figure 9) . A recent study with MDCK kidney cells showed a gastrin-induced decrease in E-cadherin and b-catenin interaction (Bierkamp et al., 2002) . Since tyrosine phosphorylation of b-catenin can modulate E-cadherin/b-catenin interaction Roura et al., 1999) , it is possible that gastrin modulates b-catenin activity via modulating its tyrosine phosphorylation. In fact, studies by Hollande et al. (2001) , showed an increase in b-catenin tyrosine phosphorylation by G-17-Gly, although it is unclear whether a similar mechanism is activated by G-17 as well. In addition, a potent activation of the p42/44 MAPKinase pathway in AGSE cells following the addition of G-17 (data not shown) might be responsible for phosphorylation and activation of CREB, as reported by others (Wu et al., 2001) . The strong phosphorylation of both CREB (Figure 6b ) and p42/ 44 MAPKinase (data not shown), induced by G-17, as well as the kinetic similarity, supported this hypothesis. Further studies are required to determine the contribution of the different signaling pathways toward G-17-mediated activation of b-catenin and CREB, leading finally to the activation of cyclin D1 transcription in GI cancer cells. Figure 9 Representative model summarizing the pathways by which G-17 induces cyclin D1 transcription: addition of G-17 to AGSE cells induces cyclin D1 transcription, which requires activation of Wnt-signaling and CREB pathways, since inhibition of each of these pathways (by dnTCF4/axin or KCREB, respectively) attenuates the induction. The addition of G-17 also activates PI3Kinase and inhibits GSK3b (data not shown), which might result in increased b-catenin levels. G-17-mediated activation of the p42/44 MAPKinase and PI3Kinase (data not shown) might induce phosphorylation and activation of CREB, which via association with CBP can activate the CRE site and induce cyclin D1 transcription
In conclusion, our studies demonstrated the mechanism by which G-17 modulated cyclin D1 transcription, and shed light on the pathway by which G-17 might be involved in GI tumorigenesis. Identification of the effectors involved will help in designing efficient therapeutic interventions to treat GI-related proliferative diseases.
Materials and methods
Reagents and plasmids
Lipofectamine and b-Gal (b-galactosidase) assay kits were from Invitrogen (Baltimore, MD, USA); G-17 from Bachem (King of Prussia, PA, USA); and luciferase assay kit from Promega (Madison, WI, USA). The antibodies used were: cyclin D1 from Neomarkers (Freemont, CA, USA); b-catenin from BD Transduction Laboratories (Franklin Lakes, NJ, USA); ABC b-catenin from Upstate Biotechnology (Lake Placid, NY, USA); HA.11 antibody from Babco (Richmond, CA, USA); and CREB (total and phospho) from Cell Signaling Technology (Beverly, MA, USA). The À1745 human cyclin D1 promoter reporter construct containing 1745 bp upstream of the transcription initiation site, À1745 CD1-luc (TCF mutant), À1745 CD1-luc (CRE mutant), À66 CD1-luc (without the TCF sites) and the empty luciferase vector pA3-luc have been described elsewhere (Joyce et al., 1999; Watanabe et al., 1998) . The pGL3OT and pGL3OF reporter constructs were from Dr Bert Vogelstein (He et al., 1998) , the pCRE-luc reporter construct was from Stratagene, HAepitope-tagged wild-type b-catenin construct from Dr Stephen Byers (Orford et al., 1997) , the wild-type CREB construct from Dr Marc Montminy (Du et al., 2000) , the KCREB construct from Dr Richard Goodman (Walton et al., 1992) , the pHYTCAxin-myc clone containing the mouse axin cDNA was from Dr Roel Nusse (Willert et al., 1999) and the dnTCF4 cDNA clone was from Dr Hans C Clevers (Korinek et al., 1997) .
Cell culture
These studies were performed using the AGSE-EF1a/CCK-B receptor cell line (AGSE), derived by stably transfecting the human gastric adenocarcinoma cell line AGS (ATCC) with the full-length human CCKB receptor, downstream from the EF1a promoter, as described previously (Raychowdhury et al., 2002) . Following selection with puromycin, the expression and activity of the CCK-B receptor was verified by Northern blotting and by inhibition of gastrin-induced HDC-luciferase promoter activity by CCK-B receptor antagonists, respectively. Subconfluent populations of AGSE cells maintained in DMEM containing 10% FBS, 100 IU/ml penicillin and 100 mg/ ml streptomycin were utilized for these studies.
Transient transfections and luciferase assay
Subconfluent AGSE cells were transfected with the luciferase and b-Gal (as control) plasmids using lipofectamine and luciferase, and b-Gal assays were performed following treatment with G-17. Each assay was performed in duplicate and each transfection was repeated at least six to nine times. The results calculated as the ratio of relative light units to the b-Gal readings (RLU/b-Gal) were expressed as % increase, with the values from controls as 100%. In the experiments with axin, dnTCF4 and KCREB, the different reporter constructs were cotransfected with the respective expression vectors.
Western blot and immunoprecipitation analysis
Equal amounts of total protein extracted from AGSE cells was subjected to Western blot and immunoprecipitation analysis, as described (Rana et al., 1995; Barthwal et al., 2003) . Proteins were detected using appropriate primary and secondary antibodies and developed using the Enhanced Chemiluminescence system (Pierce, IL, USA).
Immunofluorescence studies Double-well chamber slides containing AGSE cells treated with 100 nM G-17 were fixed in 4% methanol-free formaldehyde, permeabilized in 0.2%. Triton X-100 and subjected to immunofluorescence analysis, using b-catenin or cyclin D1 antibodies and rhodamine-conjugated anti-murine secondary antibody (Santacruz, CA, USA) as described (Singh et al., 1995) . Images were acquired using an OlymPix 2000 RGB camera and OlymPix 2000 software (1280 Â 1024 pixels/image).
Flow cytometry
AGSE cells were plated at an initial density of 10 6 cells per 100 mm dish, serum starved for 36 h and then treated in the absence or presence of 100 nM G-17. The cells were harvested at 6 and 24 h following the addition of G-17, washed in cold PBS, treated with 50 mg/ml Dnase-free RNase, stained with propidium iodide and subjected to flow cytometry and analysed using the ModFitLT DNA analysis program (Beckton Dickinson, San Jose, CA, USA).
Chromatin immunoprecipitation assay
ChIP assays were performed according to a protocol described previously (Boyd et al., 1998) . Briefly, AGSE cells transfected with wild-type HA-tagged b-catenin, in combination with either dnCREB (KCREB), dnTCF4 or EV and treated with 100 nM G-17, were crosslinked by 1% formaldehyde and nuclear extracts were isolated. The sonicated nuclear lysates were immunoprecipitated with HA antibody and the DNA recovered was subjected to PCR using the primers 5 0 -AACGTCACACGGACTACAGG-3 0 and 5 0 -TGTTCCAT-GGCTGGGGCTCTT-3 0 , spanning the putative CRE site on the cyclin D1 promoter. A similar ChIP with AGSE extracts, without any antibody, served as no antibody control and an HA-IP without any extract served as the mock IP control. The PCR products were electrophoresed on a 1% agarose gel, visualized by ethidium bromide staining and quantified by laser densitometry.
Abbreviations b-Gal, b-galactosidase; CBP, CREB-binding protein; CCKB, cholecystokinin B; ChIP, chromatin immunoprecipitation; CRE, cyclic AMP response element; CREB, CRE-binding protein; dnTCF4, dominant-negative TCF4; FACS, fluorescence-activated cell sorter; G-17, amidated gastrin; GI, gastrointestinal; H. pylori, Helicobacter pylori; LEF, lymphoid enhancer factor; PCNA, proliferating cell nuclear antigen; PI3Kinase, phosphatidylinositol 3-kinase; TCF, T-cell factor.
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